000			nab a22 7a 4500
999			_c17059 _d17059
003			PC17059
005			20221111140218.0
008			221111b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91508 _aAllende Martínez, Luis Miguel _eInmunología
245	0	0	_aHigh frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation. _h[artículo]
260			_bInternational immunology, _c2016
300			_a28(2):55-64.
500			_aFormato Vancouver: Boix Giner F, Millan O, San Segundo D, Muñoz Cacho P, Mancebo E, Llorente S et al. High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation. Int Immunol. 2016 Feb;28(2):55-64.
501			_aPMID: 26270267 PMC4885217
504			_aContiene 39 referencias
520			_aSeveral studies have analyzed the potential of T regulatory cells (Treg cells) as biomarkers of acute rejection (AR). The aim of the present multicenter study was to correlate the percentage of peripheral Treg cells in liver graft recipients drawn at baseline up to 12 months after transplantation with the presence of AR. The percentage of central memory (cm) Treg cells (CD4(+)CD25(high)CD45RO(+)CD62L(+)) was monitored at pre-transplant and at 1 and 2 weeks, and 1, 2, 3 and 6 months and 1 year post-transplantation. The same validation standard operating procedures were used in all participating centers. Fifteen patients developed AR (23.4%). Hepatitis C virus recurrence was observed in 16 recipients, who displayed low peripheral blood cmTreg levels compared with patients who did not. A steady increase of cmTregs was observed during the first month after transplantation with statistically significant differences between AR and non-AR patients. The high frequency of memory Treg cells allowed us to monitor rejection episodes during the first month post-transplantation. On the basis of these data, we developed a prediction model for assessing risk of AR that can provide clinicians with useful information for managing patients individually and customizing immunosuppressive therapies.
710			_9395 _aServicio de Inmunología
856			_uhttps://pubmed.ncbi.nlm.nih.gov/26270267/ _yAcceso libre
942			_2ddc _cART _n0